No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CYTK241220P65000
- 14.70
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
14.70Open14.70Pre Close0 Volume66 Open Interest65.00Strike Price0.00Turnover0.00%IV-2.93%PremiumDec 20, 2024Expiry Date16.13Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.10Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Why Cytokinetics Stock Was a Nearly 5% Winner Today
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi
Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China